title: 11C-acetate positron emission tomography imaging and image fusion with computed tomography and magnetic resonance imaging in patients with recurrent prostate cancer.
abstract: OBJECTIVE
  To assess the clinical value of computed tomography (CT) and magnetic resonance imaging (MRI) image fusion with 11C-acetate (AC) positron emission tomography (PET) imaging for detection and exact location of clinically occult recurrences.
  
  
  METHODS
  Fifty prostate cancer patients with elevated/increasing serum prostate-specific antigen levels after radical therapy underwent whole-body AC PET. Uptake was initially interpreted as normal, abnormal, or equivocal. In case of abnormal or equivocal uptake, additional conventional imaging techniques, such as CT, MRI, and bone scans, were performed. To precisely define the anatomic location of abnormal uptake and to improve characterization of equivocal lesions, a software-assisted image fusion (CT-PET, MRI-PET) was performed and evaluated as site-by-site analysis of 51 abnormal (n = 37) or equivocal (n = 14) sites of all 50 patients. In 17 patients, additional histopathologic evaluation was available.
  
  
  RESULTS
  In five (10%), 13 (26%), and 32 (64%) of the 50 patients, AC PET studies demonstrated AC uptake judged as normal, equivocal, and abnormal, respectively. Image fusion changed characterization of equivocal lesions as normal in five (10%) of 51 sites and abnormal in nine (18%) of 51 sites. It precisely defined the anatomic location of abnormal uptake in 37 (73%) of 51 sites. AC PET findings did influence patient management in 14 (28%) of 50 patients.
  
  
  CONCLUSIONS
  Retrospective fusion of AC PET and CT/MRI is feasible and seems to be essential for final diagnosis. This is particularly true in patients with AC uptake in the prostate region.
authors.affiliation: Department of Nuclear Medicine, Hospital Pharmacy of the General Hospital of Vienna, Medical University of Vienna, Vienna, Austria. wachter@ef1.at
authors.forename: Stefan
authors.initials: S
authors.lastname: Wachter
authors.forename: Sandra
authors.initials: S
authors.lastname: Tomek
authors.forename: Amir
authors.initials: A
authors.lastname: Kurtaran
authors.forename: Natascha
authors.initials: N
authors.lastname: Wachter-Gerstner
authors.forename: Bob
authors.initials: B
authors.lastname: Djavan
authors.forename: Alexander
authors.initials: A
authors.lastname: Becherer
authors.forename: Markus
authors.initials: M
authors.lastname: Mitterhauser
authors.forename: Georg
authors.initials: G
authors.lastname: Dobrozemsky
authors.forename: Shuren
authors.initials: S
authors.lastname: Li
authors.forename: Richard
authors.initials: R
authors.lastname: Pötter
authors.forename: Robert
authors.initials: R
authors.lastname: Dudczak
authors.forename: Kurt
authors.initials: K
authors.lastname: Kletter
mesh_terms: D000085:Acetates; D000230:Adenocarcinoma / Q000000981:diagnostic imaging / Q000556:secondary; D000368:Aged; D000369:Aged, 80 and over; D002250:Carbon Radioisotopes; D005240:Feasibility Studies; D006801:Humans; D007091:Image Processing, Computer-Assisted; D008279:Magnetic Resonance Imaging; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000000981:diagnostic imaging* / Q000473:pathology; D049268:Positron-Emission Tomography / Q000379:methods; D011468:Prostatectomy; D011471:Prostatic Neoplasms / Q000000981:diagnostic imaging* / Q000473:pathology / Q000532:radiotherapy / Q000601:surgery; D012189:Retrospective Studies; D014057:Tomography, X-Ray Computed
chemical_list: D000085:Acetates; D002250:Carbon Radioisotopes